Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with O / Omeprazole
 
Omeprazole
 

A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and zollinger-ellison syndrome. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-exchanging ATPase) in the proton pump of gastric parietal cells. [PubChem]
BrandsAntra
Audazol
Aulcer
Belmazol
Ceprandal
Danlox
Demeprazol
Desec
Dizprazol
Dudencer
Elgam
Emeproton
Epirazole
Erbolin
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
Indurgan
Inhibitron
Inhipump
Lensor
Logastric
Lomac
Losec
Mepral
Miol
Miracid
Mopral
Morecon
Nilsec
Nopramin
Ocid
Olexin
Omapren
Omebeta 20
Omed
Omegast
Omepral
Omeprazon
Omeprol
Omesek
Omezol
Omezolan
Omid
Omisec
Omizac
Ompanyt
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Prazentol
Prazidec
Prazolit
Prilosec
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
Sanamidol
Secrepina
Tedec Ulceral
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
Victrix
Zefxon
Zegerid
Zepral
Zimor
Zoltum
CategoriesAnti-Ulcer Agents
Enzyme Inhibitors
Proton-pump Inhibitors
ManufacturersApotex inc
Dr reddys laboratories ltd
Impax laboratories inc
Kremers urban development co
Lek pharmaceuticals d d
Mylan pharmaceuticals inc
Sandoz inc
Watson laboratories inc florida
Astrazeneca lp
Dexcel pharma technologies ltd
Santarus, Inc.
PackagersAidarex Pharmacuticals LLC
Altura Pharmaceuticals Inc.
Amerisource Health Services Corp.
Apotex Inc.
A-S Medication Solutions LLC
Astra Pharma Inc.
AstraZeneca Inc.
Atlantic Biologicals Corporation
Blenheim Pharmacal
Bryant Ranch Prepack
Cardinal Health
Caremark LLC
Comprehensive Consultant Services Inc.
Concern Stirol
Contract Packaging Resources Inc.
Corepharma LLC
Coupler Enterprises Inc.
CVS Pharmacy
Dept Health Central Pharmacy
Dexcel Ltd.
DHHS Program Support Center Supply Service Center
Dispensing Solutions
Diversified Healthcare Services Inc.
Doctor Reddys Laboratories Ltd.
Ftl International Inc.
Global Pharmaceuticals
Golden State Medical Supply Inc.
H.J. Harkins Co. Inc.
Heartland Repack Services LLC
Impax Laboratories Inc.
Innoviant Pharmacy Inc.
Kaiser Foundation Hospital
Keltman Pharmaceuticals Inc.
Laboratorios Dr Esteve SA
Lake Erie Medical and Surgical Supply
Lek Pharmaceuticals Inc.
Major Pharmaceuticals
Mckesson Corp.
Medisca Inc.
Medsource Pharmaceuticals
Merck & Co.
Merial Inc.
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Nucare Pharmaceuticals Inc.
Palmetto Pharmaceuticals Inc.
Par Pharmaceuticals
Patheon Inc.
PD-Rx Pharmaceuticals Inc.
Perrigo Co.
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepak Systems Inc.
Prescript Pharmaceuticals
Procter & Gamble
Ranbaxy Laboratories
Rebel Distributors Corp.
Remedy Repack
S&P Healthcare
Sandhills Packaging Inc.
Sandoz
Santarus Inc.
Schwarz Pharma Inc.
Southwood Pharmaceuticals
St Mary's Medical Park Pharmacy
Stat Rx Usa
Teva Pharmaceutical Industries Ltd.
Torpharm Inc.
UDL Laboratories
Vangard Labs Inc.
Watson Pharmaceuticals
SynonymsOMEP
Omeprazol [INN-Spanish]
Omeprazole magnesium
Omeprazolum [INN-Latin]
OMZ

indication

For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.

pharmacology

Omeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Omeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase at the secretory surface of the gastric parietal cell. As a result, it inhibits acid secretion into the gastric lumen. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.

mechanism of action

Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, omeprazole blocks the final step in acid production, thus reducing gastric acidity.

toxicity

Symptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.

biotransformation

Hepatic.

absorption

Absorption is rapid, absolute bioavailability (compared to intravenous administration) is about 30-40% at doses of 20-40 mg.

half life

0.5-1 hour

route of elimination

Urinary excretion is a primary route of excretion of omeprazole metabolites.

drug interactions

Alprazolam: Omeprazole may increase the effect of the benzodiazepine, alprazolam.

Atazanavir: This gastric pH modifier decreases the levels/effects of atazanavir

Cefditoren: Proton pump inhibitors such as omeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.

Chlordiazepoxide: Omeprazole may increase the effect of the benzodiazepine, chlordiazepoxide.

Cilostazol: Omeprazole increases the effect of cilostazol

Clonazepam: Omeprazole may increase the effect of the benzodiazepine, clonazepam.

Clopidogrel: Omeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Clopidogrel prescribing information recommends avoiding concurrent use with omeprazole, due to the possibility that combined use may result in decreased clopidogrel effectiveness.

Clorazepate: Omeprazole may increase the effect of the benzodiazepine, clorazepate.

Cyclosporine: Omeprazole increases the effect and toxicity of cyclosporine

Dasatinib: Omeprazole may decrease the serum level of dasatinib.

Diazepam: Omeprazole may increase the effect of the benzodiazepine, diazepam.

Disopyramide: The beta-blocker increases toxicity of disopyramide

Enoxacin: Omeprazole may decrease the absorption of enoxacin.

Estazolam: Omeprazole may increase the effect of the benzodiazepine, estazolam.

Ethotoin: Omeprazole increases the effect of hydantoin

Flurazepam: Omeprazole may increase the effect of the benzodiazepine, flurazepam.

Fosphenytoin: Omeprazole increases the effect of hydantoin

Halazepam: Omeprazole may increase the effect of the benzodiazepine, halazepam.

Indinavir: Omeprazole decreases the absorption of indinavir

Itraconazole: The proton pump inhibitor, omeprazole, may decrease the absorption of itraconazole.

Ketazolam: Omeprazole may increase the effect of the benzodiazepine, ketazolam.

Ketoconazole: The proton pump inhibitor, omeprazole, may decrease the absorption of ketoconazole.

Mephenytoin: Omeprazole increases the effect of hydantoin

Methotrexate: Omeprazole increases the levels of methotrexate

Midazolam: Omeprazole may increase the effect of the benzodiazepine, midazolam.

Phenytoin: Omeprazole increases the effect of hydantoin

Prazepam: Omeprazole may increase the effect of the benzodiazepine, prazepam.

Quazepam: Omeprazole may increase the effect of the benzodiazepine, quazepam.

St. John's Wort: St. John's Wort decreases the levels/effects of omeprazole

Tacrolimus: Omeprazole may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Omeprazole therapy is initiated, discontinued or altered.

Tipranavir: Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Omeprazole. Consider alternate therapy or increase the dose of Omeprazole based on the therapeutic response.

Triazolam: Omeprazole may increase the effect of the benzodiazepine, triazolam.

Trimipramine: The strong CYP2C19 inhibitor, Omeprazole, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Omeprazole is initiated, discontinued or dose changed.

Voriconazole: Voriconazole increases the effect and toxicity of omeprazole